Market Closed -
Saudi Arabian S.E.
13:20:05 09/05/2024 BST
|
5-day change
|
1st Jan Change
|
133.8
SAR
|
+0.15%
|
|
-2.90%
|
-2.34%
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
21,736
|
17,810
|
17,446
|
-
|
-
|
Enterprise Value (EV)
1 |
21,828
|
18,075
|
17,715
|
17,588
|
17,432
|
P/E ratio
|
24.5
x
|
19.9
x
|
19.4
x
|
18.1
x
|
16.8
x
|
Yield
|
-
|
4.01%
|
4.04%
|
4.43%
|
5%
|
Capitalization / Revenue
|
2.52
x
|
2.04
x
|
1.92
x
|
1.82
x
|
1.72
x
|
EV / Revenue
|
2.53
x
|
2.07
x
|
1.94
x
|
1.84
x
|
1.71
x
|
EV / EBITDA
|
13.6
x
|
11.5
x
|
11
x
|
10.2
x
|
9.57
x
|
EV / FCF
|
-
|
18.4
x
|
19.7
x
|
19.3
x
|
16.6
x
|
FCF Yield
|
-
|
5.45%
|
5.07%
|
5.18%
|
6.03%
|
Price to Book
|
9.69
x
|
7.92
x
|
6.89
x
|
6.27
x
|
5.93
x
|
Nbr of stocks (in thousands)
|
130,000
|
130,000
|
130,000
|
-
|
-
|
Reference price
2 |
167.2
|
137.0
|
133.6
|
133.6
|
133.6
|
Announcement Date
|
20/03/23
|
17/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
8,616
|
8,714
|
9,109
|
9,574
|
10,168
|
EBITDA
1 |
-
|
1,599
|
1,578
|
1,615
|
1,716
|
1,822
|
EBIT
1 |
-
|
1,003
|
961
|
953.5
|
1,024
|
1,106
|
Operating Margin
|
-
|
11.64%
|
11.03%
|
10.47%
|
10.7%
|
10.87%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
944.2
|
993.2
|
1,086
|
1,182
|
Net income
1 |
812.5
|
887.8
|
892.6
|
893.1
|
960.5
|
1,036
|
Net margin
|
-
|
10.3%
|
10.24%
|
9.8%
|
10.03%
|
10.19%
|
EPS
2 |
6.250
|
6.830
|
6.870
|
6.870
|
7.388
|
7.967
|
Free Cash Flow
1 |
-
|
-
|
984.2
|
899
|
910.7
|
1,052
|
FCF margin
|
-
|
-
|
11.3%
|
9.87%
|
9.51%
|
10.35%
|
FCF Conversion (EBITDA)
|
-
|
-
|
62.37%
|
55.67%
|
53.06%
|
57.73%
|
FCF Conversion (Net income)
|
-
|
-
|
110.26%
|
100.67%
|
94.81%
|
101.57%
|
Dividend per Share
2 |
-
|
-
|
5.500
|
5.400
|
5.918
|
6.685
|
Announcement Date
|
03/04/22
|
20/03/23
|
17/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
---|
Net sales
1 |
-
|
2,239
|
2,159
|
2,138
|
2,105
|
-
|
2,163
|
2,214
|
2,258
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
305.8
|
278.5
|
153.9
|
263.2
|
-
|
229.8
|
215.1
|
231.6
|
Operating Margin
|
-
|
13.66%
|
12.9%
|
7.2%
|
12.51%
|
-
|
10.62%
|
9.71%
|
10.26%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
237.5
|
268.5
|
253.8
|
128
|
-
|
265
|
-
|
-
|
232.9
|
Net margin
|
-
|
11.99%
|
11.76%
|
5.99%
|
-
|
-
|
-
|
-
|
10.32%
|
EPS
|
1.830
|
2.070
|
-
|
0.9900
|
-
|
2.040
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
23/05/22
|
11/08/22
|
03/11/22
|
20/03/23
|
11/05/23
|
03/08/23
|
05/11/23
|
17/03/24
|
08/05/24
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
91.8
|
265
|
269
|
142
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
14.1
|
Leverage (Debt/EBITDA)
|
-
|
0.0574
x
|
0.168
x
|
0.1668
x
|
0.0827
x
|
-
|
Free Cash Flow
1 |
-
|
-
|
984
|
899
|
911
|
1,052
|
ROE (net income / shareholders' equity)
|
-
|
46.2%
|
37.9%
|
35.9%
|
36.4%
|
36.4%
|
ROA (Net income/ Total Assets)
|
-
|
19.2%
|
17.3%
|
16.7%
|
17.2%
|
17.9%
|
Assets
1 |
-
|
4,616
|
5,158
|
5,349
|
5,575
|
5,795
|
Book Value Per Share
2 |
-
|
17.30
|
17.30
|
19.40
|
21.30
|
22.50
|
Cash Flow per Share
2 |
-
|
12.80
|
10.50
|
10.10
|
10.40
|
9.070
|
Capex
1 |
-
|
275
|
385
|
404
|
365
|
373
|
Capex / Sales
|
-
|
3.19%
|
4.41%
|
4.43%
|
3.81%
|
3.66%
|
Announcement Date
|
03/04/22
|
20/03/23
|
17/03/24
|
-
|
-
|
-
|
Last Close Price
133.6
SAR Average target price
155.4
SAR Spread / Average Target +16.34% Consensus |
1st Jan change
|
Capi.
|
---|
| -2.34% | 4.63B | | -33.68% | 14.86B | | -23.66% | 11.73B | | +12.44% | 6.3B | | -25.24% | 6.29B | | -9.39% | 6B | | +60.00% | 4.57B | | -10.84% | 3.5B | | -6.41% | 3.04B | | -4.86% | 2.78B |
Other Drug Retailers
|